Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA. |  |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Burrows Scott L | Chief Financial Officer | May 01 '26 | Option Exercise | 14.50 | 12,500 | 181,250 | 110,494 | May 01 09:35 PM | | Burrows Scott L | Chief Financial Officer | May 01 '26 | Sale | 71.37 | 12,500 | 892,125 | 97,994 | May 01 09:35 PM | | Sloan Sheldon | Chief Medical Officer | May 01 '26 | Option Exercise | 27.46 | 78,333 | 2,151,024 | 78,333 | May 01 09:34 PM | | Sloan Sheldon | Chief Medical Officer | May 01 '26 | Sale | 71.50 | 78,333 | 5,600,701 | 0 | May 01 09:34 PM | | Turtle Cameron | Chief Executive Officer | May 01 '26 | Sale | 71.37 | 15,000 | 1,070,507 | 612,540 | May 01 09:34 PM | | SHELDON SLOAN | Officer | May 01 '26 | Proposed Sale | 74.45 | 78,333 | 5,831,892 | | May 01 04:44 PM | | SCOTT BURROWS | Officer | May 01 '26 | Proposed Sale | 74.45 | 27,500 | 2,047,375 | | May 01 04:44 PM | | Turtle Cameron | Chief Executive Officer | Apr 01 '26 | Sale | 49.33 | 15,000 | 739,912 | 627,540 | Apr 03 09:30 PM | | Sloan Sheldon | Chief Medical Officer | Apr 01 '26 | Option Exercise | 21.66 | 7,958 | 172,370 | 7,958 | Apr 03 09:30 PM | | Sloan Sheldon | Chief Medical Officer | Apr 01 '26 | Sale | 50.00 | 7,958 | 397,900 | 0 | Apr 03 09:30 PM | | Burrows Scott L | Chief Financial Officer | Apr 01 '26 | Option Exercise | 14.50 | 7,500 | 108,750 | 105,494 | Apr 03 09:29 PM | | Burrows Scott L | Chief Financial Officer | Apr 01 '26 | Sale | 49.34 | 7,500 | 370,076 | 97,994 | Apr 03 09:29 PM | | SHELDON SLOAN | Officer | Apr 01 '26 | Proposed Sale | 50.44 | 7,958 | 401,402 | | Apr 01 04:38 PM | | Burrows Scott L | Chief Financial Officer | Mar 03 '26 | Option Exercise | 14.50 | 2,500 | 36,250 | 100,494 | Mar 03 09:32 PM | | Burrows Scott L | Chief Financial Officer | Mar 03 '26 | Sale | 40.65 | 2,500 | 101,620 | 97,994 | Mar 03 09:32 PM | | Turtle Cameron | Chief Executive Officer | Mar 02 '26 | Sale | 42.19 | 15,000 | 632,866 | 642,540 | Mar 03 09:31 PM | | SCOTT BURROWS | Officer | Mar 03 '26 | Proposed Sale | 42.49 | 10,000 | 424,900 | | Mar 03 04:43 PM | | CAMERON TURTLE | Director | Mar 02 '26 | Proposed Sale | 43.01 | 60,000 | 2,580,600 | | Mar 02 04:31 PM | | Turtle Cameron | Chief Executive Officer | Feb 02 '26 | Sale | 32.80 | 15,000 | 492,045 | 657,540 | Feb 04 09:33 PM | | Turtle Cameron | Chief Executive Officer | Jan 02 '26 | Sale | 30.68 | 15,000 | 460,134 | 671,907 | Jan 06 09:36 PM | | Turtle Cameron | Chief Executive Officer | Dec 01 '25 | Sale | 29.02 | 15,000 | 435,356 | 686,907 | Dec 03 09:52 PM | | Turtle Cameron | Chief Executive Officer | Nov 03 '25 | Sale | 23.33 | 45,000 | 1,049,778 | 701,907 | Nov 05 09:15 PM | | CAMERON TURTLE | Director | Nov 03 '25 | Proposed Sale | 24.46 | 90,000 | 2,201,400 | | Nov 03 04:24 PM | | Burrows Scott L | Chief Financial Officer | Sep 02 '25 | Sale | 16.26 | 18,428 | 299,639 | 97,994 | Sep 03 06:53 PM |
|
